faculty
Amie Fonder, PA-C
Physician Assistant
Mayo Clinic
Rochester, Minnesota

Target Audience

The educational design of this activity addresses the needs of hematology/oncology NPs, PAs, and nurses involved in the treatment of patients with multiple myeloma (MM).

Program Overview

How are advances in T-cell redirection changing the treatment landscape for patients with relapsed/refractory multiple myeloma (RRMM)? In this “Top 10” educational activity, physician assistant Amie Fonder addresses 10 practical questions commonly asked by advanced practice providers (APPs) caring for patients with MM. The activity explores the latest developments in bispecific antibody (BsAb) and chimeric antigen receptor (CAR) T-cell therapies, including considerations related to newly expanded treatment options. Key questions focus on recognizing, preventing, and managing common adverse events associated with these T-cell redirection therapies. The program also examines practical approaches to coordinating care across the multidisciplinary team and supporting patients throughout treatment. Designed for busy oncology APPs, this activity provides actionable insights to help clinicians navigate evolving treatment options and optimize care for patients with RRMM.

Educational Objectives

After completing this activity, the participant should be better able to:

  • Compare the clinical profiles of CAR T-cell therapies and BsAbs for MM
  • Recognize common and serious adverse events associated with CAR T-cell and BsAb therapies for RRMM
  • Incorporate key principles of CAR T-cell and BsAb therapy-associated TEAE monitoring, mitigation, and management into practice
  • Explain key care coordination considerations for patients undergoing T-cell redirection therapies, including multidisciplinary management across different practice settings

Joint Accreditation Statement

In support of improving patient care, this activity has been planned and implemented by Global Education Group and Integritas Communications. Global Education Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurse Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Nurse Contact Hours Designation

Global Education Group designates this continuing education activity for 0.75 contact hour(s) including 0.0 pharmacotherapeutic contact hour(s).

Physician Associates Credit Designation

Global Education Group has been authorized by the American Academy of Physician Associates (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.75 AAPA Category 1 CME credit(s). Approval is valid until November 13, 2027. PAs should only claim credit commensurate with the extent of their participation.

Global Contact Information

For information about the joint accreditation of this program please contact Global at 303-395-1782 or cme@globaleducationgroup.com.

Instructions to Receive Credit

In order to receive credit for this activity, the participant must complete the activity, application for credit and evaluation form. Participants must also score at least 70% on the post-test.

Fee Information & Refund/Cancellation Policy

There is no fee for this educational activity.

Disclosures of Relevant Financial Relationships

Global adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by Joint Accreditation and all other accrediting bodies, as applicable, stating those activities where CE credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited CE program provided by Global are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are appropriately identified as relevant by Global. All relevant financial relationships have been mitigated in advance of delivery of the activity to learners.

The following faculty have relevant financial relationships with ineligible companies:

Amie Fonder, PA-C: Nothing to disclose

The planners and managers at Global and Integritas have no relevant financial relationships to disclose.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global and Integritas do not recommend the use of any agent outside of the labeled indications. 

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Begin Activity
available resources
linked resources
Suggested Reading
A CME Top 10™ Activity

Top 10 Questions From Oncology NPs and PAs

Optimizing Use of BsAb and CAR T-Cell Therapy in Multiple Myeloma Management